Waters (WAT) 10-K risk factor changes: FY2020 vs FY2019
The 2020-12-31 10-K against the 2019-12-31 one, compared heading by heading and sentence by sentence.
Item 1A23 rewritten64 added4 removed150 unchanged
All filing items456 rewritten2,025 added1,853 removed962 unchanged
Sentence counts leave out repeated page headers and footers. 28 of those lines differ and are listed apart under each item.
Summary
counted, not written
- Item 1A headings could not be compared: only 0 carried over between the two years, which usually means one filing was read wrongly, so none is reported as new or removed.
- Sentence by sentence, 2,025 added, 1,853 removed, 456 rewritten and 962 unchanged across 20 items that differ.
- Not counted above: 28 repeated page header or footer lines also differ. They are listed apart under each item.
- New this year: Item 8. Financial Statements and Supplementary Data; Item 9B. Other Information; Item 13. Certain Relationships and Related Transactions and Director Independence; Item 14. Principal Accountant Fees and Services; Item 16. Form 10-K Summary.
Sentences by item
21 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2020; struck-through words were in FY2019. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. Risk Factors
23 rewritten, 64 added, 4 removed, 150 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Approximately 71% [removed: and 72%] of the Company’s net sales in [removed: 2019] [added: both 2020] and [removed: 2018, respectively,] [added: 2019] were outside of the United States and were primarily denominated in foreign currencies.
Approximately [removed: 57%] [added: 59%] and [removed: 56%] [added: 57%] of the Company’s net sales in [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] respectively, were to worldwide pharmaceutical and biotechnology companies, which may be periodically subject to unfavorable market conditions and consolidations.
Financial markets in the U.S., Europe and Asia have experienced times of extreme disruption, including, among other things, sharp increases in the cost of new capital, credit rating downgrades and bailouts, severely [removed: diminished capital availability and severely reduced liquidity in money markets.]
The Company is in the process of developing new products with recently acquired [removed: technologies.]
None of the Company’s key management employees, with the exception of the [removed: Chairman and Chief Executive Officer and the Senior Vice] President and Chief [removed: Financial] [added: Executive] Officer, have an employment contract with the Company and there can be no assurance that such individuals will remain with the Company.
[removed: If,] [added: Additionally, if,] for any reason, other [removed: such] key personnel do not continue to be active in management, the Company’s results of operations or financial condition could be adversely affected.
Certain components or modules of the Company’s LC and MS instruments are manufactured by outside contractors, including the manufacturing of LC instrument systems and related components by contract [removed: manufacturing firms in Singapore.]
We may rely on one or a few key distributors for a product or market and the loss of these [added: distributors could reduce our revenue or net earnings.]
In the event that any future climate change legislation would require that stricter standards be imposed by domestic or international environmental regulatory authorities with respect to the use and/or levels of possible [removed: emissions from such chemicals and/or other substances, the Company may be required to make certain changes and adaptations to its manufacturing processes.]
[added: Any changes in corporate income tax rates or regulations regarding transfer] pricing or repatriation of dividends or capital, as well as changes in the interpretation of existing tax laws and regulations, in the jurisdictions in which the Company operates could adversely affect the Company’s cash flow and lead to increases in its overall tax burden, which would negatively affect the Company’s profitability.
The Company has a [removed: contractual] tax [removed: rate] [added: exemption] in Singapore [added: on certain types] of [removed: 0%] [added: income] through March 2021, based upon the achievement and continued satisfaction of certain operational and financial milestones, which the Company [added: met as of December 31, 2020 and] expects to [removed: continue to meet.][added: maintain through March 2021.]
Currently, the Company has determined that it is more likely than not to realize the [removed: contractual] tax [removed: rate] [added: exemption] in Singapore [removed: of 0% and] [added: and, accordingly,] has not recognized any [removed: uncertain] [added: reserves for unrecognized] tax [removed: position in] [added: benefits on] its balance sheet related to [removed: the achievement of the contractual milestones in Singapore.][added: this tax exemption.]
In the event that [removed: it appears that] [added: any of] the milestone targets [removed: will] [added: were] not [removed: be] met, the Company [removed: will no longer] [added: would not] be entitled to [removed: a 0% contractual] [added: the] tax [removed: rate benefit] [added: exemption] on income earned in Singapore dating back to the start date of the agreement (April 1, 2016), [removed: at which time] [added: and] all [added: the] tax benefits previously [removed: recorded] [added: recognized] would be [removed: reversed and an] [added: reversed, resulting in the recognition of] income tax [removed: charge] [added: expense] equal to the statutory tax of 17% on income earned during that [removed: period would be recorded.][added: period.]
The Company had [removed: $1.7] [added: $1.4] billion in debt and [removed: $337] [added: $443] million in cash, cash equivalents and investments as of December 31, [removed: 2019.][added: 2020.]
As of December 31, [removed: 2019,] [added: 2020,] the Company also had the ability to borrow an additional [removed: $1.2] [added: $1.4] billion from its existing, committed credit facility.
Disruption, [removed: cyber attack] [added: cyber-attack] or unforeseen problems with the security, maintenance or upgrade of the Company’s information and
[added: The Company’s technology] infrastructure may be vulnerable to damage or interruption from, but not limited to, natural disasters, power loss, telecommunication failures, terrorist attacks, computer viruses, unauthorized access to customer or employee data, unauthorized access to and funds transfers from Company bank accounts and other attempts to harm the Company’s systems.
If the Company’s security measures are compromised or fail to adequately protect its technology infrastructure, research and development efforts or manufacturing operations, the Company’s products and services may be perceived as vulnerable or unreliable, the information [removed: \[protected by\]] [added: protected by] the Company’s controls and processes may be subject to unauthorized access, acquisition or modification, the Company’s brand and reputation could be damaged, the services that the Company provides to its customers could be disrupted, and customers may stop using the Company’s products and services, all of which could reduce the Company’s revenue and earnings, increase its expenses and expose the Company to legal claims and regulatory actions.
The Company is in the business of designing, manufacturing, selling and servicing analytical instruments to life science, pharmaceutical, biochemical, industrial, nutritional [removed: safety,] [added: safety] and environmental, academic and governmental customers working in research and development, quality assurance and other laboratory applications, and the Company is also a developer and supplier of software-based products that support instrument systems.
Changes in laws or regulations associated with enhanced protection of certain sensitive types of personal information, such as information related to health, could greatly increase the cost of [added: compliance and the cost of providing the Company’s products or services.]
In [removed: 2018,] [added: 2019,] the Company was not able to determine with certainty the country of origin of some of the conflict minerals in its manufactured products.
The Company is in the process of evaluating its [removed: 2019] [added: 2020] supply chain, and the Company plans to file its [removed: 2019] [added: 2020] Form SD with the SEC in May [removed: 2020.][added: 2021.]
| Item [removed: |] 1B: Unresolved [added: |] Staff Comments |
RISKS RELATED TO THE CORONAVIRUS
(COVID-19)
PANDEMIC
The Company’s business has been and may continue to be negatively affected by outbreaks of disease, such as epidemics or pandemics, including the ongoing
pandemic.
Outbreaks of disease, such as epidemics or pandemics, have and could continue to negatively affect the Company’s business.
Both the Company’s domestic and international operations have been and continue to be adversely affected by the ongoing global
pandemic and the resulting volatility and uncertainty it has caused in the U.S. and international markets.
Since being declared a pandemic in March 2020 by the World Health,
has continued to spread throughout the U.S. and globally.
The
pandemic has caused significant volatility and uncertainty in U.S. and international markets, which has disrupted and is expected to continue to disrupt the Company’s business and could result in a prolonged economic downturn.
The Company operates in over 35 countries, including those in the regions most impacted by the
pandemic.
Many countries, including the U.S., have implemented measures such as quarantine,
shelter-in-place,
curfew and similar isolation measures, including government orders and other restrictions on the conduct of business operations.
Such measures have had and are expected to continue to have adverse impacts on the U.S. and foreign economies of uncertain severity and duration and have had and may continue to have a negative impact on the Company’s operations, including the Company’s sales, supply chain and cash flow.
Certain jurisdictions have experienced increased numbers of
infections following the
re-openings
of their economies and easing of restrictions, which, in some cases, has required closings of certain business activity and the imposition of other restrictions in response.
It is unclear whether the increases in the number of infections will continue and amplify or whether any
so-called
“second waves” of
infections will be experienced in the United States or elsewhere and, if so, what the impact of that would be on human health and safety, the economy and our business.
Although the FDA has approved certain therapies and two vaccines for emergency use and distribution, the initial rollout of vaccine distribution has encountered significant delays and there remains uncertainties about the amount of vaccine available for distribution, the logistics of implementing a national vaccine program and the overall efficacy of the vaccines once widely administered, especially as new strains of
have been discovered, and the level of resistance these new strains have to the existing vaccines remains unknown.
Additionally, the widespread pandemic has caused and is expected to continue to cause significant disruption of global financial markets, which may reduce the Company’s ability to access capital.
The
pandemic also has the potential to significantly impact our supply chain if our manufacturing facilities or those of third parties to whom we outsource certain manufacturing processes, the distribution centers where our inventory is managed or the operations of our logistics and other service providers are disrupted, temporarily closed or experience worker shortages.
We may also see disruptions or delays in shipments of certain materials or components of our products.
As a result of the ongoing
pandemic, the Company has transitioned the majority of its workforce to a temporary remote working model, which may result in the Company experiencing lower workforce efficiency and productivity, which in turn may adversely affect the Company’s business, results of operations and financial condition.
As company employees work from home and access the Company’s system remotely, the Company may be subject to heightened security risks, including the risks of cyber-attacks.
Additionally, if any of the Company’s key management employees are unable to perform their duties for a period of time, including as the result of illness, the Company’s business, results of operations and financial condition could be adversely affected.
The Company cannot reasonably estimate the length or severity of the
pandemic or the related response, or the extent to which the disruption may continue to impact the Company’s business, financial position, results of operations and cash flows.
Ultimately, the
pandemic could have a material adverse impact on the Company’s business, financial positions, results of operations and cash flows.
distributors could reduce our revenue or net earnings.
Any changes in corporate income tax rates or regulations regarding transfer
The Company’s technology
compliance and the cost of providing the Company’s products or services.
An excerpt. Shown here: all 23 rewritten, 40 of 64 added and all 4 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2020 filing and the FY2019 filing.
Page headers and footers: 12 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
191 rewritten, 147 added, 99 removed, 240 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
” [removed: and] [added: and,] together with HPLC, referred to as “LC”), mass spectrometry (“MS”) and precision chemistry consumable products and related services.
The Company’s operating results are as follows for the years ended December 31, [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017] [added: 2018] (dollars in thousands, except per share data):
| | | [removed: 2019] [added: 2020] | | | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2019] [added: 2020] vs. [removed: 2018] [added: 2019] | | | | [removed: 2018] [added: 2019] vs. [removed: 2017] [added: 2018] | | |
| Product sales | | $ | [removed: 1,567,189] [added: 1,497,333] | | | $ | [removed: 1,604,993] [added: 1,567,189] | | | $ | [removed: 1,552,349] [added: 1,604,993] | | | | [removed: (2] [added: (4] | %) | | | [removed: 3] [added: (2] | [removed: %] [added: %)] |
| Service sales | | | [removed: 839,407] [added: 868,032] | | | | [removed: 814,936] [added: 839,407] | | | | [removed: 756,729] [added: 814,936] | | | | 3 | % | | | [removed: 8] [added: 3] | % |
| Total net sales | | | [removed: 2,406,596] [added: 2,365,365] | | | | [removed: 2,419,929] [added: 2,406,596] | | | | [removed: 2,309,078] [added: 2,419,929] | | | | [removed: (1] [added: (2] | %) | | | [removed: 5] [added: (1] | [removed: %] [added: %)] |
| Cost of sales | | | [removed: 1,010,700] [added: 1,006,689] | | | | [removed: 992,564] [added: 1,010,700] | | | | [removed: 947,067] [added: 992,564] | | | | [removed: 2] [added: —] | [removed: %] | | | [removed: 5] [added: 2] | % |
| Selling and administrative expenses | | | [removed: 534,791] [added: 553,698] | | | | [removed: 536,902] [added: 534,791] | | | | [removed: 544,363] [added: 536,902] | | | | [removed: —] [added: 4] | [added: %] | | | [removed: (1] [added: —] | [removed: %)] |
| Research and development expenses | | | [removed: 142,955] [added: 140,777] | | | | [removed: 143,403] [added: 142,955] | | | | [removed: 132,593] [added: 143,403] | | | | [removed: —] [added: (2] | [added: %)] | | | [removed: 8] [added: —] | [removed: %] |
| Purchased intangibles amortization | | | [removed: 9,693] [added: 10,587] | | | | [removed: 7,712] [added: 9,693] | | | | [removed: 6,743] [added: 7,712] | | | | [removed: 26] [added: 9] | % | | | [removed: 14] [added: 26] | % |
| Litigation [removed: (settlement)] provision [added: (settlement)] | | | [removed: —] [added: 1,180] | | | | [removed: (426] [added: —] | [removed: )] | | | [removed: 11,114] [added: (426] | [added: )] | | | [removed: 100] [added: *] | [removed: %] [added: *] | | | [removed: (104] [added: *] | [removed: %)] [added: *] |
| Operating income | | | [removed: 708,457] [added: 645,489] | | | | [removed: 739,774] [added: 708,457] | | | | [removed: 662,198] [added: 739,774] | | | | [removed: (4] [added: (9] | %) | | | [removed: 12] [added: (4] | [removed: %] [added: %)] |
| Operating income as a % of sales | | | [removed: 29.4] [added: 27.3] | % | | | [removed: 30.6] [added: 29.4] | % | | | [removed: 28.7] [added: 30.6] | % | | | | | | | | |
| Other expense | | | [removed: (3,586] [added: (1,775] | ) | | | [removed: (47,794] [added: (3,586] | ) | | | [removed: (340] [added: (47,794] | ) | | | [added: (51] | [added: %)] | | | [added: *] | [added: *] |
| Interest expense, net | | | [removed: (26,632] [added: (32,800] | ) | | | [removed: (9,834] [added: (26,632] | ) | | | [removed: (20,761] [added: (9,834] | ) | | | [removed: 171] [added: 23] | % | | | [removed: (53] [added: *] | [removed: %)] [added: *] |
| Income before income taxes | | | [removed: 678,239] [added: 610,914] | | | | [removed: 682,146] [added: 678,239] | | | | [removed: 641,097] [added: 682,146] | | | | [removed: (1] [added: (10] | %) | | | [removed: 6] [added: (1] | [removed: %] [added: %)] |
| Provision for income taxes | | | [removed: 86,041] [added: 89,343] | | | | [removed: 88,352] [added: 86,041] | | | | [removed: 620,786] [added: 88,352] | | | | [removed: (3] [added: 4] | [removed: %)] [added: %] | | | [removed: (86] [added: (3] | %) |
| Net income | | $ | [removed: 592,198] [added: 521,571] | | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | | [removed: —] [added: (12] | [added: %)] | | | [added: —] | |
| Net income per diluted common share | | $ | [removed: 8.69] [added: 8.36] | | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | | [removed: 14] [added: (4] | [removed: %] [added: %)] | | | [added: 14] | [added: %] |
The Company’s net sales decreased approximately [removed: 1%] [added: 2%] in [removed: 2019] [added: 2020] as compared to [removed: 2018,] [added: 2019,] and [removed: increased 5%] [added: decreased 1%] in [removed: 2018] [added: 2019] as compared to [removed: 2017.][added: 2018.]
Foreign currency translation [removed: decreased] [added: increased] sales by [removed: 2% in 2019] [added: less than 1%] and [removed: increased] [added: decreased] sales by [removed: 1%] [added: 2%] in [removed: 2018.][added: 2020 and 2019, respectively.]
Instrument system sales decreased [removed: 4%] [added: 8%] and [removed: increased 2%] [added: 4%] in [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] respectively.
Foreign currency translation [removed: decreased] [added: increased] instrument system sales by 1% in [removed: 2019] [added: 2020] and [removed: increased instrument system] [added: decreased] sales by 1% in [removed: 2018.][added: 2019.]
Recurring revenues (combined sales of precision chemistry consumables and services) increased [removed: 3%] [added: 4%] and [removed: 8%] [added: 3%] in [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] respectively, as a result of a larger installed base of customers and higher billing demand for service sales.
Recurring revenues were [added: positively] impacted by foreign [removed: currency,] [added: currency translation in 2020,] which [removed: decreased] [added: increased] sales by [removed: 2% in 2019 and increased] [added: 1%; however foreign currency translation negatively impacted] sales by 2% in [removed: 2018.][added: 2019.]
[removed: Geographically, the] [added: The] decline in the Company’s sales in 2019 was a result of increased sales in the U.S., Canada, Japan and the rest of Asia being offset by a decrease in sales in other geographies on weaker demand for our products due to uncertainty caused by macroeconomic conditions, primarily from Brexit as well as Latin America, and governmental policy changes in China.
[removed: Sales in the Americas] [added: In 2020, sales] decreased [removed: 1% in 2019 and increased 3% in 2018.][added: 2% as compared to 2019, as the]
Combined sales to industrial customers, which include material characterization, food, environmental and fine chemical markets, declined 2% in [removed: 2019] [added: both 2020] and [removed: grew 2%] [added: 2019, with foreign currency translation positively impacting sales by 1%] in [removed: 2018.][added: 2020.]
Combined sales to academic and governmental customers [removed: increased 2%] [added: decreased 16%] in [removed: 2019] [added: 2020] and [removed: 8%] [added: increased 2%] in [removed: 2018,] [added: 2019,] with [removed: the effect of] foreign currency translation [removed: decreasing] [added: having minimal impact on] sales [removed: by 1%] in [removed: 2019] [added: 2020] and [removed: increasing] [added: decreasing] sales by 1% in [removed: 2018.][added: 2019.]
Sales to [added: our] academic and governmental customers are highly dependent on when institutions receive funding to purchase our instrument systems and, as such, sales [removed: growth rates] can vary significantly from period to period.
Operating income was [removed: $708] [added: $645] million in [removed: 2019,] [added: 2020,] a decrease of [removed: 4%] [added: 9%] as compared to [removed: 2018.][added: 2019.]
The Company’s effective tax rates were [removed: 12.7%, 13.0%] [added: 14.6%, 12.7%] and [removed: 96.8%] [added: 13.0%] for [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] respectively.
Net income per diluted share was [removed: $8.69, $7.65] [added: $8.36, $8.69] and [removed: $0.25] [added: $7.65] in [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] respectively.
The Company generated [removed: $643] [added: $791] million, [removed: $604] [added: $643] million and [removed: $698] [added: $604] million of net cash flows from operations in [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] respectively.
Included in the [added: 2020 and] 2019 net cash flow from operations is [removed: $29] [added: $38] million [added: and $29 million, respectively,] of income tax payments made in the U.S. in relation to the 2017 transition tax liability.
Over the next [removed: three] [added: two] years, the Company is required to make annual U.S. federal tax payments of approximately $38 million to tax authorities in connection with the Company’s estimated remaining transition tax liabilities of [removed: $404] [added: $365] million under the 2017 Tax Act.
Cash flows used in investing activities included capital expenditures related to property, plant, equipment and software capitalization of [removed: $164] [added: $172] million, [removed: $96] [added: $164] million and [removed: $85] [added: $96] million in [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] respectively.
[removed: In 2019, $68] [added: The cash flows from investing activities in 2020 also included $70] million of capital expenditures [removed: paid] related to the expansion of the Company’s precision chemistry consumable operations in the U.S. The Company has incurred [removed: $85] [added: $151] million [removed: of costs for] [added: on] this facility through the end of [removed: 2019.][added: 2020 and anticipates spending a total of $215 million to build and equip this]
During [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] the Company repurchased [removed: 11.1] [added: 0.8] million, [removed: 6.8] [added: 11.1] million and [removed: 1.8] [added: 6.8] million shares of the Company’s outstanding common stock at a cost of [added: $167 million,] $2.5 [removed: billion, $1.3] billion and [removed: $323 million,] [added: $1.3 billion,] respectively, under the January 2019 authorization and other previously announced programs.
As of December 31, [removed: 2019,] [added: 2020,] the Company has a total of [removed: $1.7] [added: $1.5] billion authorized for future repurchases.
Both the Company’s domestic and international operations have been and continue to be adversely affected by the ongoing global pandemic of a novel strain of coronavirus
(“COVID-19”)
that has led to volatility and uncertainty in the U.S. and international markets.
The Company is actively managing its business to respond to the
impact; however, the Company cannot reasonably estimate the length or severity of the
pandemic or the related response, or the extent to which the disruption may materially impact the Company’s business, consolidated financial position, consolidated results of operations or consolidated cash flows in the future.
In 2020, the
pandemic did not materially impact the Company’s manufacturing facilities or those of the third parties to whom it outsources certain manufacturing processes, the distribution centers where its inventory is managed, or the operations of its logistics and other service providers.
The Company also did not see material disruptions or delays in shipments of certain materials or components of its products.
At every stage of the pandemic, the Company has taken decisive and appropriate actions, including a mandatory remote work policy for all employees with the exception of those in manufacturing, distribution, and certain laboratory environments, as well as restrictions on
non-essential
travel and visitors into its facilities.
The Company has engaged a medical advisor to guide its policy deployment, and the Company continues to take proactive measures to guard the health of its global employee base, and the safety of all customer interactions.
The Company has implemented rigorous protocols to promote a safe work environment in all of its locations around the world and continues to closely monitor and update its multi-phase process that was developed during the year to ensure for the safe return of employees to its physical workplaces as social distancing, governmental requirements and other protocols allow.
The vast majority of the markets the Company serves, most notably the pharmaceutical, biomedical research, food/environmental and clinical markets, have continued to operate at various levels, and the Company is working closely with these customers to facilitate their seamless operation.
Over the last several years, the Company has executed on a digital workplace strategy focused on providing modern connectivity and
collaboration tools to its employees.
The Company’s strategic technology investments have enabled it to swiftly meet remote working needs as the
situation has escalated and evolved.
From a customer-facing perspective, the Company is leveraging digital demand generation activities, including virtual demos across all regions in which it operates, remote instrument installations, virtual sales seminars, online product training, and a rapid acceleration in
one-on-one
communications over emails, phone and video conferencing.
While the Company initially anticipated that the
pandemic would have the biggest impact on the Company’s financial results in the second quarter of 2020, and future quarters would improve as countries lifted their business restrictions, the new outbreaks of
in the U.S. and elsewhere throughout the world have demonstrated that the
pandemic continues to be fluid with uncertainties and risks remaining across the global economy.
The Company took a proactive approach to managing through this unpredictability and implemented a series of cost reduction actions that include salary reductions, furloughs and reductions in
non-essential
spending and other working capital reductions in order to preserve liquidity and enhance financial flexibility.
These cost reductions were completed by the end of 2020; however, the Company’s plan will be adjusted accordingly depending on the pace of the recovery and any further lockdowns.
| Asset impairments | | | 6,945 | | | | — | | | | — | | | | * | * | | | — | |
The decline in sales in 2020 can be attributed to the lower customer demand due to interruption in business activities caused by the uncertainties from the
COVID-19 pandemic
across the world.
The negative impact of
on our business was more pronounced in the first half of 2020 as the Company’s sales declined 12% as compared to the prior year.
In the second half of 2020, our customers began to resume laboratory and manufacturing operations and it resulted in the Company’s second half sales growing 7% as compared to the prior year.
The Company’s acquisitions of Andrew Alliance (as defined below) and ISS (as defined below) did not have material impacts on sales growth in 2020.
In 2020, the decrease in instrument system sales was attributable to the weaker demand for our products by our customers due to interruption of business activities and the uncertainty caused by
the COVID-19 pandemic.
| Acquired in-process research and development | | | — | | | | — | | | | 5,000 | | | | — | | | | (100 | %) |
In 2018, the increase in instrument system sales was primarily driven by an increase in demand for LC and TA’s instrument systems.
In addition, the effect of foreign currency translation negatively impacted sales by 2% overall.
The Company’s sales growth in 2018 was primarily driven by the 7% sales growth in Asia, with China’s sales growing 15%.
Sales in Europe decreased 4% in 2019 and increased 4% in 2018.
In 2019, Europe sales were impacted by weak demand in Western Europe caused by the political uncertainties of Brexit and the effect of foreign currency translation, which reduced sales by 4% in 2019 and increased sales by 3% in 2018.
The Americas sales in 2019 were negatively impacted by macroeconomic conditions in Latin America, and the 2018 Americas sales growth can be attributed to the increase in sales after the lower customer demand stemming from the 2017 natural disasters in the U.S., Mexico and Puerto Rico.
Sales to pharmaceutical customers were flat in 2019 and grew 5% in 2018.
Sales to pharmaceutical customers in 2019 were negatively impacted by the lower customer demand in China for our instrument systems as a result of changes in governmental policy and lower sales in Latin America.
Despite the sales declines in China and Latin America, the need for global access to prescription drugs and the testing of newer and complex biologic drugs increased in the rest of the world.
The 2019 industrial customer sales were negatively impacted by a 6% decline in TA instrument system sales and a 1% decline from the effect of foreign currency translation.
Operating income increased 12% in 2018 as compared to 2017.
This increase was primarily a result of the effect of higher sales volume achieved in 2018, as well as the effect of approximately $33 million of facility closure, litigation and intellectual property payment charges from 2017 that did not recur in 2018.
In 2017, The Company incurred a $550 million income tax provision related to the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”) which reduced the net income per diluted share by $6.82, and excluding the 2017 Tax Act income tax provision, the Company’s effective tax rate in 2017 would have been 11.0%.
In 2018, the Company acquired the sole intellectual property rights to the Desorption Electrospray Ionization (“DESI”) imaging technology for $30 million in cash and a future contractual obligation to pay a minimum royalty of $3 million over the remaining life of the patent.
DESI is a mass spectrometry imaging technique that is used to develop medical therapies.
In September 2019, the Company issued fixed interest rate senior unsecured notes with an aggregate principal amount of $500 million, of which $200 million of the outstanding notes matures in seven years and the remaining $300 million matures in 10 years.
The Company used the proceeds from the issuance of these senior unsecured notes to repay other outstanding debt and for general corporate purposes.
U.S.-to-Euro
In January 2020, the Company made organizational changes to better align its resources with its growth and innovation strategies, resulting in a worldwide workforce reduction, impacting 3% of the Company’s employees.
The Company expects to incur approximately $25 million of severance costs, lease termination costs and other related costs during 2020.
In January 2020, the Company entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics for approximately $80 million.
In 2018, sales in China increased across all product lines and were driven by double-digit increases in sales to pharmaceutical, academic and governmental customers.
The effect of foreign currency translation increased sales in Japan by 2% in 2018 and sales growth was also driven by increased sales to pharmaceutical and industrial customers.
The sales decline in Asia Other in 2018 was a result of lower customer demand in India and weaker sales to environmental customers in the first quarter of 2018.
In 2018, sales growth in Europe was driven by TA’s products and services and recurring revenues to pharmaceutical and industrial customers.
Sales growth in the U.S. in 2018 was driven by recurring revenues and TA instruments.
Sales in the rest of the Americas had double-digit sales growth for instrument systems and double-digit sales growth for pharmaceutical customers, which was offset by a decline in sales to industrial customers.
In 2018, sales to pharmaceutical customers were driven by recurring revenues, with double-digit growth in China, Canada and Latin America.
Sales growth for the industrial market in 2018 was driven by TA products and services, and
mid-single-digit
sales growth in Europe, Japan and India.
Precision chemistry consumables sales increased in both 2019 and 2018, driven by sales in the U.S. and China, primarily to pharmaceutical customers, on the uptake in columns and application-specific testing kits.
Waters instrument system sales (LC and MS technology-based) decreased in 2019 in most major geographical regions, primarily due to lower sales to pharmaceutical and industrial customers due to uncertainty caused by macroeconomic conditions relating to Brexit and other regulatory changes in certain regions.
In 2018, Waters sales increased 7% in Asia, 4% in Europe and 2% in the Americas.
Waters sales increased 15% in China in 2018 and were broad-based across all product classes, with double-digit increases in sales to pharmaceutical, academic and governmental customers.
Sales in Asia Other declined 2% in 2018, primarily due to lower customer demand in India and a negative 2% impact of foreign currency translation.
In the Americas, U.S. sales increased 1% in 2018.
TA sales in the U.S. increased 9% in 2018, while sales in the rest of the Americas increased 8%.
TA’s sales in Asia were driven by double-digit sales growth in India and 8% sales growth in China, which was offset by declines in Japan.
An excerpt. Shown here: 40 of 191 rewritten, 40 of 147 added and 40 of 99 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2020 filing and the FY2019 filing.
Page headers and footers: 10 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
COVID-19
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
27 rewritten, 0 added, 1,627 removed, 35 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
[added: |] Foreign [removed: Currency Exchange Contracts][added: currency exchange contracts: | | | | | | | | | | | | | | |]
[added: |] Interest [removed: Rate Cross-Currency Swap Agreements][added: rate cross-currency swap agreements: | | | | | | | | | | | | | | |]
As of December 31, [removed: 2019,] [added: 2020,] the Company has entered into three-year interest rate cross-currency swap derivative agreements with a notional value of $560 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.
[removed: Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency] translation adjustment in other comprehensive income and remain in accumulated comprehensive income in stockholders’ [removed: (deficit)] equity [added: (deficit)] until the sale or substantial liquidation of the foreign operation.
| | | December 31, [removed: 2019] [added: 2020] | | | | | | | | December 31, [removed: 2018] [added: 2019] | | | | | | |
| Other current assets | | $ | [removed: 119,576] [added: 66,690] | | | $ | [removed: 16] [added: 836] | | | $ | [removed: 112,212] [added: 119,576] | | | $ | [removed: 503] [added: 16] | |
| Other current liabilities | | $ | [removed: 29,495] [added: 20,000] | | | $ | [removed: 1,028] [added: 185] | | | $ | [removed: 40,175] [added: 29,495] | | | $ | [removed: 224] [added: 1,028] | |
| Other [added: (liabilities)] assets | | $ | 560,000 | | | $ | [removed: 4,485] [added: (44,996] | [added: )] | | $ | [removed: 300,000] [added: 560,000] | | | $ | [removed: 1,093] [added: 4,485] | |
| Accumulated other comprehensive [removed: income] [added: loss (income)] | | | | | | $ | [removed: (4,485] [added: 44,996] | [removed: )] | | | | | | $ | [removed: (1,093] [added: (4,485] | ) |
| | | Financial Statement Classification | | | | | | | | | | | | | [removed: | |]
| | [added: |] Year Ended December 31, | | | | | | | | | | | | | [removed: | | |]
| | [removed: 2019] | [removed: | |] [added: 2020] | [removed: 2018] | | | [added: 2019] | [removed: 2017] | | | [added: 2018] | | | | |
| Realized [removed: (losses)] gains [added: (losses)] on closed contracts | | [removed: |] Cost of sales | | [removed: |] $ | [removed: (3,552] [added: 1,444] | [removed: )] | | $ | [removed: (6,684] [added: (3,552] | ) | | $ | [removed: 3,894] [added: (6,684] | [added: )] |
| Unrealized [removed: (losses)] gains [added: (losses)] on open contracts | | [removed: |] Cost of sales | | | [removed: | (1,292] [added: 1,663] | [removed: )] | | | [removed: (105] [added: (1,292] | ) | | | [removed: 1,054] [added: (105] | [added: )] |
| Cumulative net pre-tax [removed: (losses)] gains [removed: |] [added: (losses)] | | Cost of sales | | [removed: |] $ | [removed: (4,844] [added: 3,107] | [removed: )] | | $ | [removed: (6,789] [added: (4,844] | ) | | $ | [removed: 4,948] [added: (6,789] | [added: )] |
| Interest earned | | [removed: |] Interest income | | [removed: |] $ | [removed: 11,709] [added: 15,296] | | | $ | [removed: 2,713] [added: 11,709] | | | $ | [removed: —] [added: 2,713] | |
| Unrealized [added: (losses)] gains on open contracts | | [removed: |] Stockholders’ [removed: (deficit)] equity [removed: |] [added: (deficit)] | | $ | [removed: 4,485] [added: (44,996] | [added: )] | | $ | [removed: 1,093] [added: 4,485] | | | $ | [removed: —] [added: 1,093] | |
exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of December 31, [removed: 2019] [added: 2020] would decrease
earnings by approximately [removed: $15] [added: $9] million.
exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of December 31, [removed: 2019] [added: 2020] would increase by approximately $56 million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ [removed: (deficit) equity.][added: equity (deficit).]
As of December 31, [removed: 2019,] [added: 2020,] the carrying value of the Company’s cash and cash equivalents approximated fair value.
As of December 31, [removed: 2019,] [added: 2020,] the Company estimates that a hypothetical adverse change of 100 basis points across all maturities would not have a material effect on the fair market value of its portfolio.
As of December 31, [removed: 2019] [added: 2020] and [removed: 2018, $249] [added: 2019, $364] million out of [removed: $337] [added: $443] million and [removed: $471] [added: $249] million out of [removed: $1,735] [added: $337] million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries.
In addition, [removed: $176] [added: $254] million out of [removed: $337] [added: $443] million and [removed: $251] [added: $176] million out of [removed: $1,735] [added: $337] million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at December 31, [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] respectively.
As of December 31, [removed: 2019,] [added: 2020,] the Company had no holdings in auction rate securities or commercial paper issued by structured investment vehicles.
exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash, cash equivalents and investments held in currencies other than the U.S. dollar as of December 31, [removed: 2019] [added: 2020] would decrease by approximately [removed: $18] [added: $25] million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ [removed: (deficit) equity.][added: equity (deficit).]
Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency [removed: translation adjustment in]
Derivative Transactions
The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates.
The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its
non-U.S.
The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against
corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.
The Company presents the derivative transactions in financing activities in the statement of cash flows.
The Company does not specifically enter into any derivatives that hedge foreign-currency-denominated operating assets, liabilities or commitments on its balance sheet, other than a portion of certain third-party accounts receivable and accounts payable, and the Company’s net worldwide intercompany receivables and payables, which are eliminated in consolidation.
The foreign currency exchange contracts are not designated for hedge accounting treatment.
Principal hedged currencies include the Euro, Japanese yen, British pound, Mexican peso and Brazilian real.
The difference between the interest rate received and paid under the interest rate cross-currency swap derivative agreement is recorded in interest income in the statement of operations.
The Company’s foreign currency exchange contracts and interest rate cross-currency swap agreements included in the consolidated balance sheets are classified as follows (in thousands):
| | | Notional Value | | | | Fair Value | | | | Notional Value | | | | Fair Value | | |
| Foreign currency exchange contracts: | | | | | | | | | | | | | | | | |
| Interest rate cross-currency swap agreements: | | | | | | | | | | | | | | | | |
The following is a summary of the activity included in the statements of comprehensive income related to the foreign currency exchange contracts (in thousands):
| Foreign currency exchange contracts: | | | | | | | | | | | | | | | | |
| Interest rate cross-currency swap agreements: | | | | | | | | | | | | | | | | |
pre-tax
pre-tax
The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar.
| Item | 8: Financial Statements and Supplementary Data |
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules
13a-15(f)
and
15d-15(f)
under the Exchange Act.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in
Internal Control — Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based on our evaluation under the framework in
Internal Control — Integrated Framework (2013)
, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2019.
The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Waters Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
An excerpt. Shown here: all 27 rewritten, all 0 added and 40 of 1,627 removed. The counts are complete. For every sentence, read Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the FY2020 filing and the FY2019 filing.
Item 1. Business
34 rewritten, 79 added, 27 removed, 358 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
The Company primarily designs, manufactures, sells and services high performance liquid chromatography (“HPLC”), [removed: ultra performance] [added: ultra-performance] liquid chromatography (“UPLC
For these reasons, the Company’s customers and field sales and support organizations are well positioned to utilize this [removed: new] [added: innovative] technology and instrument.
are often used to analyze the role of proteins in disease [added: processes, an application sometimes referred to as “proteomics”.]
UNIFI joins Waters’ suite of [removed: informatics products – Empower]
[added: The customer] benefits from improved budget control, data-driven technology adoption and accelerated workflow at a site or on a global perspective.
The servicing and support of instruments, software and accessories is an important source of revenue and represented over 35% of sales for Waters in [removed: 2019.][added: 2020.]
In addition, systems and accompanying software packages can be tailored for specific [removed: applications][added: applications.]
Similar to Waters, the servicing and support of TA’s instruments is an important source of revenue and represented more than 25% of sales for TA in [removed: 2019.][added: 2020.]
During [removed: 2019, 57%] [added: 2020, 59%] of the Company’s net sales were to pharmaceutical accounts, 30% to other industrial accounts and [removed: 13%] [added: 11%] to academic institutions and governmental agencies.
During fiscal years [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] no single customer accounted for more than 2% of the Company’s net sales.
Across these product technologies, using respective specialized sales and service workforces, the Company serves its customer base with [removed: 56] [added: 83] sales offices throughout the world as of December 31, [removed: 2019] [added: 2020] and approximately 4,000, [removed: 3,900] [added: 4,000] and [removed: 3,800] [added: 3,900] field representatives in [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] respectively.
The Company’s sales representatives have direct responsibility for account relationships, while service representatives work in the field to install instruments, train customers and minimize [added: instrument downtime.]
The Company has incurred [removed: $85] [added: $151] million of costs on this facility through the end of [removed: 2019.][added: 2020.]
[removed: The instruments, components or] modules are then returned to the Company’s facilities, where its engineers perform final assembly, calibrations to customer specifications and quality control procedures.
In [removed: 2018,] [added: 2019,] the Company was not able to determine with certainty the country of origin of some of the conflict minerals in its manufactured products.
The Company is in the process of evaluating its [removed: 2019] [added: 2020] supply chain, and the Company plans to file its [removed: 2019] [added: 2020] Form SD with the SEC in May [removed: 2020.][added: 2021.]
, under the caption “About Waters / [removed: Environmental Health & Safety”.][added: Corporate Governance”.]
The Company’s research and development expenditures for [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017] [added: 2018] were [removed: $143] [added: $141] million, $143 million and [removed: $133] [added: $143] million, respectively.
[removed: research and development related] [added: In addition, the Company is party] to [removed: milestone payments associated with a] [added: an existing] licensing arrangement for certain intellectual property relating to mass spectrometry technologies yet to be commercialized and for which there was no future alternative use as of the acquisition date.
At December 31, [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] there were [removed: 1,089, 1,011] [added: 1,112, 1,089] and [removed: 1,004] [added: 1,011] employees, respectively, involved in the Company’s research and development efforts.
The Company employed approximately [added: 7,400,] 7,500 [added: and 7,200] employees at December 31, [removed: 2019 and 7,200 at both] [added: 2020,] December 31, [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018, respectively,] with approximately [removed: 39%] [added: 38%] of the Company’s employees located in the United States.
[removed: The Company firmly believes] [added: We believe] that [removed: its] [added: our] future success [removed: largely] depends [removed: upon its] [added: in a significant part on our] continued ability to attract and retain highly skilled [added: employees and then contribute to the growth and development of these] employees.
The Company is subject to foreign and U.S. federal, state and local laws, regulations and ordinances that (i) govern activities or operations that may have adverse environmental effects, such as discharges to air and [added: water as well as handling and disposal practices for solid and hazardous wastes, and (ii) impose liability for the costs of cleaning up and certain damages resulting from sites of past spills, disposals or other releases of hazardous substances.]
The Company also makes available, free of charge on its website, its annual report on [removed: Form]
quarterly reports on [removed: Form]
current reports on [removed: Form]
[removed: including the information incorporated by reference herein, may contain forward-looking statements with respect to future results and events, including any statements regarding, among other items, anticipated trends or growth in the Company’s business, including, but not limited to,] [added: pandemic;] the impact of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the impact of foreign currency translation on financial results; development of products by acquired businesses; the growth rate of sales and research and development expenses; the impact of costs associated with developing new technologies and bringing these new technologies to market; the impact of new product launches and the associated costs, such as the amortization expense related to software platforms; geographic sales mix of business; development of products by acquired businesses and the amount of contingent payments to the sellers of an acquired business; anticipated expenses, including interest expense, capitalized software costs and effective tax rates; the impact of the Tax Cuts and Jobs Act (the “2017 Tax Act”) in the U.S.; the impact and outcome of the Company’s various ongoing tax audit examinations; the achievement of contractual milestones to preserve foreign tax rates; the impact and outcome of litigation matters; the impact of the loss of intellectual property protection; the impact of new accounting standards and pronouncements; the adequacy of the Company’s supply chain and manufacturing capabilities and facilities; the impact of regulatory compliance; the Company’s expected cash flow, borrowing capacity, debt repayment and refinancing; the Company’s ability to fund working capital, capital expenditures, service debt, [removed: repay outstanding lines of credit, make authorized share repurchases, fund potential acquisitions and pay any adverse litigation or tax audit liabilities, particularly in the U.S.; future impairment charges; the Company’s contributions to defined benefit plans; the Company’s expectations regarding changes to its financial position; compliance with applicable environmental laws; and the impact of recent acquisitions on sales and earnings.]
Statements that are not statements of historical [added: fact may be deemed forward-looking statements.]
| | • | [added: |] Foreign currency exchange rate fluctuations that could adversely affect translation of the Company’s future sales, financial operating results and the condition of its non-U.S. operations, especially when a currency weakens against the U.S. dollar. |
| | • | [added: |] Current global economic, sovereign and political conditions and uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations; the United Kingdom’s exit from the European Union, as well as the Chinese government’s ongoing tightening of restrictions on procurement by government-funded customers; the Company’s ability to access capital and maintain liquidity in volatile market conditions; changes in timing and demand for the Company’s products among the Company’s customers and various market sectors, particularly if they should reduce capital expenditures or are unable to obtain funding, as in the cases of academic, governmental and research institutions; the effect of mergers and acquisitions on customer demand for the Company’s products; and the Company’s ability to sustain and enhance service. |
| | • | [added: |] Negative industry trends; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company’s competitors; introduction of competing products by other companies and loss of market share; pressures on prices from customers or resulting from competition; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products; expansion of our business in developing markets; spending by certain end-markets; ability to obtain alternative sources for components and modules; and the possibility that future sales of new products related to acquisitions, which trigger contingent purchase payments, may exceed the Company’s expectations. |
| | • | [added: |] Increased regulatory burdens as the Company’s business evolves, especially with respect to the FDA and EPA, among others, as well as regulatory, environmental and logistical obstacles affecting the distribution of the Company’s products, including the impact, if any, of the coronavirus in China or elsewhere; completion of purchase order documentation by our customers; and the customers’ ability to obtain letters of credit or other financing alternatives. |
| | • | [added: |] Risks associated with lawsuits, particularly involving claims for infringement of patents and other intellectual property rights. |
| | [removed: • | The impact and costs incurred from changes in accounting principles and practices; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates,] specifically as it relates to the 2017 Tax Act in the U.S.; shifts in taxable income among jurisdictions with different effective tax rates; and the outcome of and costs associated with ongoing and future tax audit examinations or changes in respective country legislation affecting the Company’s effective rates. |
Business
In 2020, the Company introduced the Waters Arc
HPLC System, a new HPLC system for routine testing in the pharmaceutical, food, academic and materials markets.
A key target application is quality control in laboratories performing batch release tests on small molecule pharmaceuticals.
In 2020, Waters introduced ACQUITY
PREMIER Columns, a new family of premium
sub-2-micron
columns featuring MaxPeak
high-performance surface technology.
The columns are for use with any brand of UPLC system and can measurably improve data quality by mitigating the loss of sample analytes due to
analyte-to-surface
interactions.
In 2020, the Company acquired all of the outstanding stock of Andrew Alliance, S.A. and its two operating subsidiaries, Andrew Alliance USA, Inc. and Andrew Alliance France, SASU (collectively, “Andrew Alliance”), for $80 million, net of cash acquired.
Andrew Alliance offers lab workflow automation solutions with the combination of its software platform and smart, connected laboratory equipment and accessories.
The Company expects the acquisition to positively impact our customers’ workflows by improving the repeatability, performance and speed of laboratory operations and chemistry workflows.
In 2020, the Company introduced the new RADIAN
ASAP
System, a novel direct mass detector engineered for
non-mass
spectrometry experts to conduct fast and accurate analyses of solids and liquids with minimal sample prep.
Also in 2020, the Company introduced enhancements for the Waters Xevo
G2-XS
QTof SYNAPT XS and SELECT SERIES Cyclic IMS, including a new fragmentation technique and imaging option.
informatics products – Empower
TM
In 2020, Waters announced the availability of Waters Empower BC LAC/E
TM
with SecureSync, a newly enhanced data
back-up
and recovery solution purpose-built for organizations with distributed laboratory environments.
On December 15, 2020, the Company acquired all of the outstanding stock of Integrated Software Solutions Pty Limited and its two operating subsidiaries Integrated Software Solutions Limited and Integrated Software Solutions USA, LLC (collectively, “ISS”), for $4 million, net of cash acquired.
In addition, the Company may have to pay additional consideration which has an estimated fair value of $1 million as of the close date.
The contingent consideration is recorded as a liability and will be paid to the prior shareholders of ISS if certain revenue and customer account conditions are achieved over the next two years after the acquisition date.
ISS offers clinical laboratory software systems that will support and further expand product offerings within our clinical business.
The net assets acquired primarily relate to ISS’ laboratory information system,
OMNI-Lab.
TM
In 2020, TA introduced the new Discovery X3 Differential Scanning Calorimeter, Discovery Hybrid Rheometers and TAM IV Micro XL isothermal microcalorimeter.
These products support the development of next-generation, high-performance materials by improving the productivity and efficiency of materials science research.
[](#toc)
processes, an application sometimes referred to as “proteomics”.
The customer
In 2017, TA introduced the TAM Air microcalorimeter.
Although designed to characterize the curing of cement, this instrument is an ideal platform for imaginative experimental design in a wide range of applications, including cement and concrete, material science, food, pharmaceuticals and environmental analysis.
TA also introduced three new dilatometer product lines in its 800 platform, which are high precision systems designed to measure dimensional changes of a specimen brought about by dynamic thermal events in a wide range of applications, including material science, ceramics and metals.
In 2017, TA introduced the Discovery SDT 650, which provides a true simultaneous measurement of weight change and differential heat flow using advanced technologies, such as dual sample TGA, modulated DSC and modulated and
hi-resolution
TGA.
In addition, TA introduced the Discovery
HP-TGA750,
a benchtop high pressure TGA that utilizes a patented ultra-high resolution magnetic suspension balance and new high precision temperature control system.
Late in 2017, TA introduced the Discovery DMA 850, which measures the viscoelastic mechanical properties of material under controlled conditions of temperature, environment and mechanical stimulus (stress or strain).
The DMA 850 features frictionless air bearing supports and a linear optical encoder, which ensures stable, accurate, high-resolution displacement measurement across the full travel range and enables displacement control of 5 nm.
In 2017, TA introduced the WinTest
8.0 software package, which will be standard on all new ElectroForce
products.
In addition, TA introduced the ElectroForce DMA 3200 in 2017, which combines fatigue and dynamic mechanical analysis into a single mechanical test platform.
instrument downtime.
The Company manufactures specialty Supercritical Fluid Chromatography (“SFC”) and Supercritical Fluid Extraction (“SFE”) products in its facility in Sharpsburg, Pennsylvania.
The Sharpsburg facility is aligned with the policies and procedures for product manufacturing and distribution as adhered to in the Milford, Massachusetts facility and is under the same structural leadership organization.
In addition, in 2017, the Company incurred a $5 million charge for acquired
in-process
water as well as handling and disposal practices for solid and hazardous wastes, and (ii) impose liability for the costs of cleaning up and certain damages resulting from sites of past spills, disposals or other releases of hazardous substances.
10-K,
10-Q,
8-K
fact may be deemed forward-looking statements.
An excerpt. Shown here: all 34 rewritten, 40 of 79 added and all 27 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2020 filing and the FY2019 filing.
Page headers and footers: 3 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
COVID-19
COVID-19
Cover and table of contents
39 rewritten, 10 added, 11 removed, 45 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
[removed: UNITED STATES] SECURITIES AND EXCHANGE COMMISSION
Form [added: 10-K]
For the fiscal year ended December 31, [removed: 2019][added: 2020]
[added: (508)] 478-2000
| Securities registered pursuant to Section 12(b) of the Act: | [removed: | |]
Yes [added: ☑ No ☐]
Yes [added: ☐ No ☑]
Yes [added: ☑]
Yes [added: ☑ No ☐]
See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in [removed: Rule]
[added: Rule] 12b-2
| Large accelerated filer ☑ | | Accelerated filer ☐ | | Non-accelerated filer ☐ | [added: |] Smaller reporting company ☐ |
| | | | | | [added: |] Emerging growth company ☐ |
Indicate by check mark whether the registrant is a shell company (as defined in [removed: Rule]
[added: Rule] 12b-2
Yes [added: ☐ No ☑]
of the registrant as of [removed: June]
Indicate the number of shares outstanding of the registrant’s common stock as of February [removed: 21, 2020: 62,158,045]
Portions of the registrant’s definitive proxy statement that will be filed for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders are incorporated by reference in Part III.
| | 1A. | | | [Risk [removed: Factors](#toc862312_2)] [added: Factors](#tx32803_2)] | | | [removed: 12] [added: 15] | |
| | 1B. | | | [Unresolved Staff [removed: Comments](#toc862312_3)] [added: Comments](#tx32803_3)] | | | [removed: 19] [added: 24] | |
| | 3. | | | [Legal [removed: Proceedings](#toc862312_5)] [added: Proceedings](#tx32803_5)] | | | [removed: 20] [added: 25] | |
| | 4. | | | [Mine Safety [removed: Disclosures](#toc862312_6)] [added: Disclosures](#tx32803_6)] | | | [removed: 20] [added: 25] | |
| | | | | [Information About Out Executive [removed: Officers](#toc862312_7)] [added: Officers](#tx32803_7)] | | | [removed: 20] [added: 25] | |
| | 5. | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#toc862312_8)] [added: Securities](#tx32803_8)] | | | [removed: 22] [added: 27] | |
| | 6. | | | [Selected Financial [removed: Data](#toc862312_9)] [added: Data](#tx32803_9)] | | | [removed: 25] [added: 30] | |
| | 7. | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#toc862312_10)] [added: Operations](#tx32803_10)] | | | [removed: 26] [added: 31] | |
| | 7A. | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#toc862312_11)] [added: Risk](#tx32803_11)] | | | [removed: 43] [added: 49] | |
| | 8. | | | [Financial Statements and Supplementary [removed: Data](#toc862312_12)] [added: Data](#tx32803_12)] | | | [removed: 46] [added: 52] | |
| | 9. | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#toc862312_13)] [added: Disclosure](#tx32803_13)] | | | [removed: 96] [added: 104] | |
| | 9A. | | | [Controls and [removed: Procedures](#toc862312_14)] [added: Procedures](#tx32803_14)] | | | [removed: 96] [added: 104] | |
| | 9B. | | | [Other [removed: Information](#toc862312_15)] [added: Information](#tx32803_15)] | | | [removed: 96] [added: 104] | |
| | 10. | | | [Directors, Executive Officers and Corporate [removed: Governance](#toc862312_16)] [added: Governance](#tx32803_16)] | | | [removed: 97] [added: 105] | |
| | 11. | | | [Executive [removed: Compensation](#toc862312_17)] [added: Compensation](#tx32803_17)] | | | [removed: 97] [added: 105] | |
| | 12. | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#toc862312_18)] [added: Matters](#tx32803_18)] | | | [removed: 97] [added: 105] | |
| | 13. | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#toc862312_19)] [added: Independence](#tx32803_19)] | | | [removed: 98] [added: 106] | |
| | 14. | | | [Principal Accountant Fees and [removed: Services](#toc862312_20)] [added: Services](#tx32803_20)] | | | [removed: 98] [added: 106] | |
| | 15. | | | [Exhibits and Financial Statement [removed: Schedules](#toc862312_21)] [added: Schedules](#tx32803_21)] | | | [removed: 99] [added: 107] | |
| | 16. | | | [Form 10-K [removed: Summary](#toc862312_22)] [added: Summary](#tx32803_22)] | | | [removed: 103] [added: 111] | |
##### [Table of Contents](#toc)
UNITED STATES
No ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
6/27/2020: $
10,820,434,917.
, 2021: 62,185,690
| | 1. | | | [Business](#tx32803_1) | | | 3 | |
| | 2. | | | [Properties](#tx32803_4) | | | 24 | |
| | | | | [Signatures](#tx32803_23) | | | 112 | |
10-K
(508)
No
No
No
No
No
, 2019: $14,554,561,947.
| | 1. | | | [Business](#toc862312_1) | | | 1 | |
| | 2. | | | [Properties](#toc862312_4) | | | 19 | |
| | | | | [Signatures](#toc862312_23) | | | 104 | |
Item 2. Properties
23 rewritten, 10 added, 13 removed, 9 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Waters Corporation operates [removed: 23] [added: 20] United States facilities and [removed: 67] [added: 71] international facilities, including field offices.
| Location | | Function (1) | | [removed: | |] Owned/Leased | [removed: | |]
| Golden, CO | | [removed: |] M, R, S, D, A | | [removed: | |] Leased | [removed: |]
| New Castle, DE | | [removed: |] M, R, S, D, A | | [removed: | |] Owned | [removed: |]
| Franklin, MA | | [removed: |] D | | [removed: | |] Leased | [removed: |]
| Milford, MA | | [removed: |] M, R, S, A | | [removed: | |] Owned | [removed: |]
| Taunton, MA | | [removed: |] M, R | | [removed: | |] Owned | [removed: |]
| Cambridge, MA | | [removed: |] R, S | | [removed: | |] Leased | [removed: |]
| Eden Prairie, MN | | [removed: |] M, R, S, D, A | | [removed: | |] Leased | [removed: |]
| Nixa, MO | | [removed: |] M, S, D, A | | [removed: | |] Leased | [removed: |]
| Lindon, UT | | [removed: |] M, R, S, D, A | | [removed: | |] Leased | [removed: |]
| Newcastle, England | | [removed: |] R, S, D, A | | [removed: | |] Leased | [removed: |]
| Solihull, England | | [removed: |] M,A | | [removed: | |] Owned | [removed: |]
| Wilmslow, England | | [removed: |] M, R, S, D, A | | [removed: | |] Owned | [removed: |]
| St. Quentin, France | | [removed: |] S, A | | [removed: | |] Leased | [removed: |]
| Huellhorst, Germany | | [removed: |] M, R, S, D, A | | [removed: | |] Owned | [removed: |]
| Budapest, Hungary | | [removed: |] R | | [removed: | |] Leased | [removed: |]
| Wexford, Ireland | | [removed: |] M, R, D, A | | [removed: | |] Owned | [removed: |]
| Etten-Leur, Netherlands | | [removed: |] S, D, A | | [removed: | |] Owned | [removed: |]
| Brasov, Romania | | [removed: |] R, A | | [removed: | |] Leased | [removed: |]
| Singapore | | [removed: |] R, S, D, A | | [removed: | |] Leased | [removed: |]
The Company operates and maintains [removed: 11] [added: 10] field offices in the United States and [removed: 56] [added: 59] field offices abroad in addition to sales offices in the primary facilities listed above.
| Costa Mesa, CA | | Australia | | [removed: India] [added: Hungary] | | [removed: Portugal] [added: Norway] |
| Bangalore, India | | M, S, D, A | | Owned |
| Pleasanton, CA | | Austria | | India | | People’s Republic of China |
| Wood Dale, IL | | Belgium | | Ireland | | Portugal |
| Carmel, IN | | Brazil | | Israel | | Poland |
| Columbia, MD | | Canada | | Italy | | Spain |
| Morrisville, NC | | Czech Republic | | Japan | | Sweden |
| Parsippany, NJ | | Denmark | | Korea | | Switzerland |
| Plymouth Meeting, PA | | Finland | | Malaysia | | Taiwan |
| Bellaire, TX | | France | | Mexico | | United Arab Emirates |
| Salt Lake City, UT | | Germany | | Netherlands | | United Kingdom |
| Wakefield, MA | | | M, R, S, D, A | | | | Leased | |
| Sharpsburg, PA | | | M, R, S, D, A | | | | Leased | |
| Bochum, Germany | | | R, S, A | | | | Leased | |
| Pleasanton, CA | | Austria | | Ireland | | Poland |
| Wood Dale, IL | | Belgium | | Israel | | Puerto Rico |
| Carmel, IN | | Brazil | | Italy | | Spain |
| Columbia, MD | | Canada | | Japan | | Sweden |
| Beverly, MA | | Czech Republic | | Korea | | Switzerland |
| Durham, NC | | Denmark | | Malaysia | | Taiwan |
| Morrisville, NC | | Finland | | Mexico | | United Kingdom |
| Parsippany, NJ | | France | | Netherlands | | |
| Plymouth Meeting, PA | | Germany | | Norway | | |
| Bellaire, TX | | Hungary | | People’s Republic of China | | |
Item 4. Mine Safety Disclosures
8 rewritten, 24 added, 16 removed, 19 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Keeley Aleman, [removed: 43,] [added: 44,] was appointed Senior Vice President, General Counsel and Secretary in October of 2019.
Carson, [removed: 46,] [added: 47,] was appointed Senior Vice President, Corporate Development in February 2018.
Harrington, [removed: 59,] [added: 60,] was appointed Senior Vice President, Global Markets in February 2016.
Pratt, [removed: 50,] [added: 51,] was appointed Senior Vice President and President, TA Instruments in August 2019.
Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life [removed: Sciences.][added: Sciences from January 2017 to April 2019.]
Additionally, he held senior positions at Pall [removed: Corporation,] [added: Corporation from 2001 to 2017,] where he was [added: Vice] President [added: and General Manager from October 2015 to December 2016 following Pall Corporation’s acquisition by Danaher Corporation and, prior to that, President] of its Food & Beverage, Laboratory and ForteBio [removed: businesses.][added: businesses from April 2011 to October 2015.]
[removed: Francis Kim, 53,] [added: King, 64,] was appointed Senior Vice President, Global [removed: Operations] [added: Products] in [removed: February 2018.][added: July 2017.]
Prior to joining Waters Corporation, [removed: she] [added: he] held senior [removed: human resources] [added: operations and engineering] positions [removed: in retail, healthcare] [added: at semiconductor] and [removed: financial services] [added: solar energy] companies.
Dr. Udit Batra, 50, was appointed a Director of the Company as well as President and CEO on September 1, 2020.
He most recently served as Chief Executive Officer of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the United States and Canada, and as a member of its Executive Board, roles he held from 2014 and 2016, respectively, through July 2020.
Prior to that, Dr. Batra served as President and Chief Executive Officer of Merck KGaA, Darmstadt, Germany’s Consumer Health business.
Dr. Batra oversaw the company’s Bioethics Advisory Panel and had Board responsibility for the global Information Technology function.
Before joining Merck KGaA, Darmstadt, Germany, Dr. Batra held several positions of increasing responsibility at Novartis, including Global Head of Corporate Strategy in Switzerland, Country President for the Pharma Business of Novartis in Australia and New Zealand and the Global Head of Public Health and Market Access in Cambridge, Massachusetts.
Dr. Batra also served at the global consultancy McKinsey & Company across the healthcare, consumer and
non-profit
sectors.
Dr. Batra started his career at Merck Research Labs in West Point, Pennsylvania as a research engineer.
Belinda Hyde, 50, was appointed Senior Vice President, Global Human Resources of Waters Corporation in January 2021.
She is responsible for all aspects of the Global Human Resources function including talent management, total rewards, HR business partners, HR operations and technology, employee engagement and diversity and inclusion.
Prior to joining Waters, Belinda served as the Chief Human Resources Officer for SPX FLOW, from July 2015 to December 2020, and Schnitzer Steel.
She has also held leadership roles in business and cultural transformation, executive development, talent management, compensation, benefits, training, internal communications and business partner support at companies such as Caltex Petroleum, Dell Technologies, Invitrogen and Celanese Corporation.
Belinda earned a Bachelor of Arts in psychology from the University of Texas, as well as both a master’s degree and doctorate in industrial and organizational psychology from the University of Houston.
In August 2020, Mr. Pratt was appointed to the Board of SPX FLOW, Inc. (NYSE:FLOW) as an independent director and a member of the Audit, Compensation, and Nominating & Governance Committees.
Michael F.
Silveira, 54, was elected by the Board of Directors of the Company to serve as the interim Chief Financial Officer, effective January 1, 2021.
Mr. Silveira has been with the Company for 16 years and is a Certified Public Accountant.
He joined Waters Corporation in 2004 as Assistant Corporate Controller and was most recently appointed Vice President and Corporate Controller in 2013.
Prior to joining the Company, he held several financial management positions with
Astro-Med,
Inc (nka AstroNova), Textron, Inc. and KPMG.
Dan Welch, 59, was appointed Senior Vice President, Global Operations in July 2020 and was Vice President of Global Supply Chain since July 2019 and Senior Director, Supply Chain Management since August 2017.
Mr. Welch joined Waters Corporation in May 2012 as General Manager and Senior Director of Manufacturing Operations.
Christopher J.
O’Connell, 53, has served as a Director of the Company since September 2015, when he assumed the position of President and Chief Executive Officer of the Company.
In December 2017, Mr. O’Connell was appointed as the Chairman of the Board of Directors of the Company.
Mr. O’Connell served as Executive Vice President and President of Restorative Therapies Group of Medtronic plc from August 2009 to August 2015.
From 1994 to August 2009, Mr. O’Connell served in the following positions at Medtronic plc: Senior Vice President and President of Medtronic Diabetes, President of Medtronic Physio-Control, Vice President of Sales and Marketing for the Cardiac Rhythm Management business, Vice President/General Manager of the Patient Management Business, Vice President of Corporate Strategy, Director of Investor Relations and Corporate Development Associate.
Sherry L.
Buck, 56, was appointed Senior Vice President and Chief Financial Officer in January 2017.
Previously, Ms. Buck served as the Vice President, Chief Financial Officer of Libbey Inc. since August 2012.
From 1993 to 2012, Ms. Buck held several positions at Whirlpool Corporation, including Vice President, Finance/Chief Financial Officer, Global Product and Enterprise Cost Leadership; Vice President, Finance—US; Vice President, Cost Leadership; Vice President, Finance—International; and Vice President, Business Performance Management.
Mr. Kim previously served as Vice President of Global Quality Assurance since November 2016.
Prior to joining Waters Corporation, he held several positions during his 20 years at Medtronic plc, including Vice President of Quality, Restorative Therapies Group from May 2015 to November 2016 and Vice President of Quality, Regulatory and Clinical Affairs, Surgical Technologies Division from January 2011 to May 2015.
On February 17, 2020, Mr. Kim notified the Company that he will be resigning his position on March 16, 2020.
King, 63, was appointed Senior Vice President, Global Products in July 2017.
Elizabeth B.
Rae, 62, was appointed Senior Vice President, Global Human Resources in February 2016 and was Vice President of Human Resources since October 2005 and Vice President of Worldwide Compensation and Benefits since January 2002.
Ms. Rae joined Waters Corporation in January 1996 as Director of Worldwide Compensation.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
10 rewritten, 8 added, 8 removed, 12 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
As of February [removed: 21, 2020,] [added: 19, 2021,] the Company had [removed: 80] [added: 78] common stockholders of record.
The Company has not made any sales of unregistered equity securities in the years ended December 31, [removed: 2019, 2018] [added: 2020, 2019] or [removed: 2017.][added: 2018.]
The following graph compares the cumulative total return on $100 invested as of December 31, [removed: 2014] [added: 2015] (the last day of public trading of the Company’s common stock in fiscal year [removed: 2014)] [added: 2015)] through December 31, [removed: 2019] [added: 2020] (the last day of public trading of the common stock in fiscal year [removed: 2019)] [added: 2020)] in the Company’s common stock, the NYSE Market Index, the SIC Code 3826 Index and the S&P 500 Index.
COMPARISON OF CUMULATIVE TOTAL RETURN SINCE DECEMBER 31, [removed: 2014][added: 2015]
[removed: ][added: ]
| | | [removed: 2014 | | | |] 2015 | | | | 2016 | | | | 2017 | | | | 2018 | | | | 2019 | | | | [added: 2020 | | |]
The following table provides information about purchases by the Company during the three months ended December 31, [removed: 2019] [added: 2020] of equity securities registered by the Company under the Exchange Act (in thousands, except per share data):
| Period | | Total Number of Shares Purchased (1) | | | | Average Price Paid per Share | | | | Total Number of Shares Purchased as Part of Publicly Announced Programs [removed: (2)] | | | | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Programs (2) | | |
| (1) | The [removed: Company’s repurchase activity] [added: Company repurchased less than one thousand shares of common stock at a cost of less than $1 million] related to the vesting of restricted stock [removed: units] during the three months ended December 31, [removed: 2019 was insignificant.] [added: 2020.] |
| (2) | In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This new program replaced the remaining amounts available under the pre-existing authorization. [added: During the second quarter of 2020, the Company temporarily suspended its share repurchases due to the uncertain business conditions caused by the COVID-19 pandemic. In December 2020, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2023.] |
| WATERS CORPORATION | | | 100.00 | | | | 99.86 | | | | 143.55 | | | | 140.18 | | | | 173.61 | | | | 183.85 | |
| NYSE MARKET INDEX | | | 100.00 | | | | 111.94 | | | | 132.90 | | | | 121.01 | | | | 151.87 | | | | 162.49 | |
| SIC CODE INDEX | | | 100.00 | | | | 111.96 | | | | 136.40 | | | | 130.42 | | | | 171.49 | | | | 203.04 | |
| S&P 500 INDEX | | | 100.00 | | | | 92.16 | | | | 141.00 | | | | 148.46 | | | | 185.11 | | | | 229.68 | |
| September 27, 2020 to October 24, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| October 25, 2020 to November 21, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| November 22, 2020 to December 31, 2020 | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| Total | | | — | | | $ | — | | | | — | | | $ | 1,524,905 | |
| WATERS CORPORATION | | $ | 100.00 | | | $ | 119.39 | | | $ | 119.22 | | | $ | 171.39 | | | $ | 167.36 | | | $ | 207.28 | | |
| NYSE MARKET INDEX | | $ | 100.00 | | | $ | 95.91 | | | $ | 107.36 | | | $ | 127.46 | | | $ | 116.06 | | | $ | 145.66 | | |
| SIC CODE INDEX | | $ | 100.00 | | | $ | 111.14 | | | $ | 102.42 | | | $ | 156.71 | | | $ | 165.13 | | | $ | 205.80 | | |
| S&P 500 INDEX | | $ | 100.00 | | | $ | 101.38 | | | $ | 113.51 | | | $ | 138.29 | | | $ | 132.23 | | | $ | 173.86 | | |
| September 29, 2019 to October 26, 2019 | | | 646 | | | $ | 217.06 | | | | 646 | | | $ | 2,112,901 | |
| October 27, 2019 to November 23, 2019 | | | 797 | | | $ | 214.93 | | | | 797 | | | $ | 1,941,602 | |
| November 24, 2019 to December 31, 2019 | | | 1,092 | | | $ | 228.96 | | | | 1,092 | | | $ | 1,691,643 | |
| Total | | | 2,535 | | | $ | 221.52 | | | | 2,535 | | | $ | 1,691,643 | |
Item 6. Selected Financial Data
18 rewritten, 0 added, 0 removed, 18 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
The statement of operations and balance sheet data is derived from financial statements for the years [added: 2020,] 2019, 2018, [removed: 2017, 2016] [added: 2017] and [removed: 2015.][added: 2016.]
The Company’s financial statements as of December 31, [removed: 2019] [added: 2020] and [removed: 2018,] [added: 2019,] and for each of the three years in the period ended December 31, [removed: 2019] [added: 2020] are included in Part II, Item 8, Financial Statements and Supplementary Data, of this Form
| In thousands, except per share and employees data | | [removed: 2019] [added: 2020] | | | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2016] [added: 2017] | | | | [removed: 2015] [added: 2016] | | |
| Net sales | | $ | [removed: 2,406,596] [added: 2,365,365] | | | $ | [removed: 2,419,929] [added: 2,406,596] | | | $ | [removed: 2,309,078] [added: 2,419,929] | | | $ | [removed: 2,167,423] [added: 2,309,078] | | | $ | [removed: 2,042,332] [added: 2,167,423] | |
| Income from operations before income taxes | | $ | [removed: 678,239] [added: 610,914] | | | $ | [removed: 682,146] [added: 678,239] | | | $ | [removed: 641,097] [added: 682,146] | | | $ | [removed: 600,114] [added: 641,097] | | | $ | [removed: 541,918] [added: 600,114] | |
| Net income* | | $ | [removed: 592,198] [added: 521,571] | | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | $ | [removed: 521,503] [added: 20,311] | | | $ | [removed: 469,275] [added: 521,503] | |
| Net income per basic common share* | | $ | [removed: 8.76] [added: 8.40] | | | $ | [removed: 7.71] [added: 8.76] | | | $ | [removed: 0.25] [added: 7.71] | | | $ | [removed: 6.46] [added: 0.25] | | | $ | [removed: 5.70] [added: 6.46] | |
| Weighted-average number of basic common shares | | | [removed: 67,627] [added: 62,094] | | | | [removed: 76,992] [added: 67,627] | | | | [removed: 79,793] [added: 76,992] | | | | [removed: 80,786] [added: 79,793] | | | | [removed: 82,336] [added: 80,786] | |
| Net income per diluted common share* | | $ | [removed: 8.69] [added: 8.36] | | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | $ | [removed: 6.41] [added: 0.25] | | | $ | [removed: 5.65] [added: 6.41] | |
| Weighted-average number of diluted common shares and equivalents | | | [removed: 68,166] [added: 62,414] | | | | [removed: 77,618] [added: 68,166] | | | | [removed: 80,604] [added: 77,618] | | | | [removed: 81,417] [added: 80,604] | | | | [removed: 83,087] [added: 81,417] | |
| Cash, cash equivalents and investments | | $ | [removed: 337,144] [added: 443,146] | | | $ | [removed: 1,735,224] [added: 337,144] | | | $ | [removed: 3,393,701] [added: 1,735,224] | | | $ | [removed: 2,813,032] [added: 3,393,701] | | | $ | [removed: 2,399,263] [added: 2,813,032] | |
| Working capital, including current maturities of debt | | $ | [removed: 721,157] [added: 596,050] | | | $ | [removed: 2,214,232] [added: 721,157] | | | $ | [removed: 3,663,977] [added: 2,214,232] | | | $ | [removed: 3,115,124] [added: 3,663,977] | | | $ | [removed: 2,649,457] [added: 3,115,124] | |
| Total assets | | $ | [removed: 2,557,055] [added: 2,839,920] | | | $ | [removed: 3,727,426] [added: 2,557,055] | | | $ | [removed: 5,324,354] [added: 3,727,426] | | | $ | [removed: 4,662,059] [added: 5,324,354] | | | $ | [removed: 4,268,677] [added: 4,662,059] | |
| Long-term debt | | $ | [removed: 1,580,797] [added: 1,206,515] | | | $ | [removed: 1,148,172] [added: 1,580,797] | | | $ | [removed: 1,897,501] [added: 1,148,172] | | | $ | [removed: 1,701,966] [added: 1,897,501] | | | $ | [removed: 1,493,027] [added: 1,701,966] | |
| Stockholders’ [removed: (deficit) equity*] [added: equity (deficit)*] | | $ | [removed: (216,281] [added: 232,144] | [removed: )] | | $ | [removed: 1,567,258] [added: (216,281] | [added: )] | | $ | [removed: 2,233,788] [added: 1,567,258] | | | $ | [removed: 2,301,949] [added: 2,233,788] | | | $ | [removed: 2,058,851] [added: 2,301,949] | |
| Employees | | | [removed: 7,467] [added: 7,412] | | | | [removed: 7,246] [added: 7,467] | | | | [removed: 7,020] [added: 7,246] | | | | [removed: 6,899] [added: 7,020] | | | | [removed: 6,594] [added: 6,899] | |
In [removed: 2019, 2018] [added: 2020, 2019] and [removed: 2017,] [added: 2018,] the Company recognized an excess tax benefit, which decreased income tax expense by [removed: $9] [added: $7] million, $9 million and [removed: $20] [added: $9] million, respectively, and added [removed: $0.14, $0.11] [added: $0.11, $0.14] and [removed: $0.24,] [added: $0.11,] respectively, to net income per diluted share.
| | In January 2019, the company adopted new accounting guidance related to the accounting for leases. The new guidance requires lessees to present the assets and liabilities that arise from leases on their balance sheets. The standard required using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. As a result, the Company recorded a $93 million right-of-use asset as of December 31, 2019. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows and [removed: stockholder’s (deficit) equity.] [added: stockholders’ equity (deficit).] |
Item 8. Financial Statements and Supplementary Data
0 rewritten, 1,619 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2020 item · filed February 24, 2021
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in
Rules 13a-15(f)
and
15d-15(f)
under the Exchange Act.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in
Internal Control
— Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
Based on our evaluation under the framework in
Internal Control
— Integrated Framework (2013)
, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2020.
The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Waters Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations, of comprehensive income, of stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the “consolidated financial statements”).
We also have audited the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in
Internal Control—Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America.
Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in
Internal Control—Integrated Framework
(2013) issued by the COSO.
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.
Basis for Opinions
The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting.
Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.
An excerpt. Shown here: all 0 rewritten, 40 of 1,619 added and all 0 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2020 filing.
Page headers and footers: 3 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
COVID-19
COVID-19
COVID-19
Item 9. :
1 rewritten, 1 added, 0 removed, 1 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Changes in and Disagreements with Accountants on Accounting and [removed: Financial Disclosure]
Financial Disclosure
Item 9A. Controls and Procedures
9 rewritten, 2 added, 3 removed, 11 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
The Company’s chief executive officer and chief financial officer (principal executive officer and principal financial officer), with the participation of management, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in [removed: Rules]
[added: Rules] 13a-15(e)
under the [added: Securities] Exchange [removed: Act)] [added: Act of 1934,] as [added: amended (the “Exchange Act”)) as] of the end of the period covered by this annual report on Form
Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2019] [added: 2020] (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
See Management’s Report on Internal Control Over Financial Reporting in Item 8 on page [removed: 46 of this Form]
See the report of PricewaterhouseCoopers LLP in Item 8 beginning on page [removed: 47 of this Form]
No change was identified in the Company’s internal control over financial reporting (as defined in [removed: Rules]
[added: Rules] 13a-15(f)
under the Exchange Act) during the quarter ended December 31, [removed: 2019] [added: 2020] that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
of this Form
of this Form
| Item 9B: Other | Information |
None.
PART III
Item 9B. Other Information
0 rewritten, 3 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2020 item · filed February 24, 2021
Other Information
None.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
4 rewritten, 1 added, 1 removed, 15 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Information regarding the Company’s directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors is contained in the definitive proxy statement for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders under the headings “Election of Directors”, “Directors Meetings and Board Committees”, “Corporate Governance”, “Report of the Audit Committee of the Board of Directors” and “Compensation of Directors and Executive Officers”.
Information regarding compliance with Section 16(a) of the Exchange Act is contained in the Company’s definitive proxy statement for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders under the heading “Delinquent Section 16(a) Reports”.
Information regarding the Company’s Audit Committee and Audit Committee Financial Expert is contained in the definitive proxy statement for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders under the headings “Report of the Audit Committee of the Board of Directors” and “Directors Meetings and Board Committees”.
Information regarding the Company’s executive officers is contained in Part I of this [removed: Form]
Form 10-K.
10-K.
Item 11. Executive Compensation
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
This information is contained in the Company’s definitive proxy statement for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders under the headings “Compensation of Directors and Executive Officers”, “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report”.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
4 rewritten, 1 added, 8 removed, 6 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
Except for the Equity Compensation Plan information set forth below, this information is contained in the Company’s definitive proxy statement for the [removed: 2020] [added: 2021] Annual Meeting of Stockholders under the heading “Security Ownership of Certain Beneficial Owners and Management”.
The following table provides information as of December 31, [removed: 2019] [added: 2020] about the Company’s common stock that may be issued upon the exercise of options, warrants and rights under its existing equity compensation plans (in thousands):
| Equity compensation plans approved by security holders | | | [removed: 1,861] [added: 1,476] | | | $ | [removed: 158.61] [added: 179.59] | | | | [removed: 2,711] [added: 7,195] | |
| (1) | Column (a) includes an aggregate of [removed: 406] [added: 408] shares of common stock to be issued upon settlement of restricted stock, restricted stock units and performance stock units. The weighted-average share price in column (b) does not take into account restricted stock, restricted stock units or performance stock units, which do not have an exercise price. |
| Total | | | 1,476 | | | $ | 179.59 | | | | 7,195 | |
Such information is incorporated herein by reference.
| Total | | | 1,861 | | | $ | 158.61 | | | | 2,711 | |
| Item | 13: Certain Relationships and Related Transactions and Director Independence |
This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.
Such information is incorporated herein by reference.
| Item | 14: Principal Accountant Fees and Services |
This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.
PART IV
Item 13. Certain Relationships and Related Transactions and Director Independence
0 rewritten, 2 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2020 item · filed February 24, 2021
This information is contained in the Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.
Such information is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
0 rewritten, 3 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2020 item · filed February 24, 2021
This information is contained in the Company’s definitive proxy statement for the 2021 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.
Such information is incorporated herein by reference.
PART IV
Item 15. Exhibits, Financial Statement Schedules
64 rewritten, 17 added, 36 removed, 39 unchanged
Read the full itemFY2020 item · filed February 24, 2021FY2019 item · filed February 25, 2020
The consolidated financial statements of the Company and its subsidiaries are filed as part of this [removed: Form]
and are set forth on pages [removed: 50] [added: 56] to [removed: 95.][added: 103.]
The report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, dated February [removed: 25, 2020,] [added: 24, 2021,] is set forth beginning on page [removed: 47] [added: 53] of this [removed: Form]
| Exhibit Number | | [removed: | |] Description of Document |
| [removed: |] 3.1 | | [removed: |] Second Amended and Restated Certificate of Incorporation of Waters Corporation.(1)(P) |
| [removed: |] 3.2 | | [removed: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 12, 1999.(3)](http://www.sec.gov/Archives/edgar/data/1000697/000104746999030964/0001047469-99-030964.txt) |
| [removed: |] 3.3 | | [removed: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of July 27, 2000.(4)](http://www.sec.gov/Archives/edgar/data/1000697/000091205700035253/ex-3_12.txt) |
| [removed: |] 3.4 | | [removed: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 25, 2001.(5)](http://www.sec.gov/Archives/edgar/data/1000697/000092701602001727/dex313.txt) |
| [removed: |] 3.5 | | [removed: |] [Amended and Restated Bylaws of Waters Corporation, dated as of [removed: December 5, 2017.(29)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517364940/d470585dex31.htm)] [added: October 8, 2020.(33)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520266377/d95602dex31.htm)] |
| [removed: |] 4.1 | | [removed: |] [Description of Registrant’s [removed: Securities](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/d862312dex41.htm)] [added: Securities](https://www.sec.gov/Archives/edgar/data/1000697/000119312521054385/d32803dex41.htm)] |
| [removed: |] 10.1 | | [removed: |] Waters Corporation Retirement Plan.(2)(P)(*) |
| [removed: |] 10.2 | | [removed: |] [Waters Corporation 2003 Equity Incentive Plan.(6)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013503005751/b48537wcexv4w1.txt) |
| [removed: |] 10.3 | | [removed: |] [First Amendment to the Waters Corporation 2003 Equity Incentive Plan.(7)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504001254/b48994wcexv10w17.txt) |
| [removed: |] 10.4 | | [removed: |] [Form of Director Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w27.txt) |
| [removed: |] 10.5 | | [removed: |] [Form of Director Restricted Stock Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w28.txt) |
| [removed: |] 10.6 | | [removed: |] [Form of Executive Officer Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w29.txt) |
| [removed: |] 10.7 | | [removed: |] [Second Amendment to the Waters Corporation 2003 Equity Incentive Plan.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013505004504/b55598wcexv10w38.htm) |
| [removed: |] 10.8 | | [removed: |] [Third Amendment to the Waters Corporation 2003 Equity Incentive Plan.(10)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507001300/b63656wcexv10w48.txt) |
| [removed: |] 10.9 | | [removed: |] [Amended and Restated Waters 401(k) Restoration Plan, effective January 1, 2008.(11)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507006667/b67183wcexv10w52.htm) |
| [removed: |] 10.10 | | [removed: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Mark T. Beaudouin.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w53.htm) |
| [removed: |] 10.11 | | [removed: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Elizabeth B. Rae.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w58.htm) |
| [removed: |] 10.12 | | [removed: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Eugene G. Cassis.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1014.htm) |
| Exhibit Number | | [removed: | |] Description of Document |
| [removed: |] 10.13 | | [removed: |] [Amended and Restated Waters Retirement Restoration Plan, effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w49.htm) |
| [removed: |] 10.14 | | [removed: |] [Amended and Restated Waters Corporation 1996 Non-Employee Director Deferred Compensation Plan, Effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w5.htm) |
| [removed: |] 10.15 | | [removed: |] [2014 Waters Corporation Management Incentive Plan.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1017.htm) |
| [removed: |] 10.16 | | [removed: |] [Waters Corporation 2009 Employee Stock Purchase Plan.(14)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095012309021422/b76149wcexv4w1.htm) |
| [removed: |] 10.17 | | [removed: |] [Note Purchase Agreement, dated as of February 1, 2010, between Waters Corporation and the purchases named therein.(15)](http://www.sec.gov/Archives/edgar/data/1000697/000095012310017583/b78684exv10w61.htm) |
| [removed: |] 10.18 | | [removed: |] [First Amendment to the Note Purchase Agreement, dated as of February 1, 2010.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w63.htm) |
| [removed: |] 10.19 | | [removed: |] [Note Purchase Agreement, dated March 15, 2011, between Waters Corporation and the purchases named therein.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w62.htm) |
| [removed: |] 10.20 | | [removed: |] [Waters Corporation 2012 Equity Incentive Plan.(17)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512380231/d404655dex41.htm) |
| [removed: |] 10.21 | | [removed: |] [Form of Waters 2012 Stock Option Agreement - Executive Officers.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex101.htm) |
| [removed: |] 10.22 | | [removed: |] [Form of Waters 2012 Stock Option Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex102.htm) |
| [removed: |] 10.23 | | [removed: |] [Form of Waters 2012 Restricted Stock Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex103.htm) |
| [removed: |] 10.24 | | [removed: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - Five Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex101.htm) |
| [removed: |] 10.25 | | [removed: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - One Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex102.htm) |
| [removed: |] 10.26 | | [removed: |] [Note Purchase Agreement, dated June 30, 2014, between Waters Corporation and the purchases named therein.(20)](http://www.sec.gov/Archives/edgar/data/1000697/000119312514290679/d760078dex101.htm) |
| [removed: |] 10.27 | | [removed: |] [Change of Control/Severance Agreement, dated as of April 1, 2015, between Waters Corporation and Michael F. Silveira.(22)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515178581/d919579dex101.htm) |
| [removed: |] 10.28 | | [removed: |] [President and Chief Executive Employment Agreement.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex101.htm) |
| [removed: |] 10.29 | | [removed: |] [Change of Control/Severance Agreement, dated as of September 8, 2015, between Waters Corporation and Christopher J. O’Connell.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex102.htm) |
Form 10-K
Form 10-K.
| 10.44 | | [Chief Executive Officer Transition and Separation Agreement, dated June 17, 2020, between Waters Corporation and Christopher J. O’Connell.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex101.htm) |
| 10.45 | | [President and Chief Executive Employment Agreement, dated July 14, 2020, between Waters Corporation and Udit Batra.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex102.htm) |
| 10.46 | | [Change of Control/Severance Agreement, dated as of July 14, 2020, between Waters Corporation and Udit Batra.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex103.htm) |
| 10.47 | | [Waters Corporation 2020 Equity Incentive Plan.(35)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520163573/d923348dex41.htm) |
| 10.48 | | [Employee Form of Stock Option Award Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex104.htm) |
| 10.49 | | [Director Form of Stock Option Award Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex105.htm) |
| 10.50 | | [Form of RSU Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex106.htm) |
| 10.51 | | [CEO Form of PSU Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex107.htm) |
| 10.52 | | [Employee (Non-CEO) PSU Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex108.htm) |
| 10.53 | | [Director Form of RSA Agreement under the Waters Corporation 2020 Equity Incentive Plan.(34)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312520202145/d944177dex109.htm) |
| (33) | Incorporated by reference to the Registrant’s Report on Form 8-K dated October 8, 2020 (File No. 001-14010). |
| (34) | Incorporated by reference to the Registrant’s Report on Form 10-Q dated July 29, 2020 (File No. 001-14010). |
| (35) | Incorporated by reference to Exhibit 4.2 of the Registration Statement filed on Form S-8 dated June 8, 2020 (File No. 333-239020). |
| (36) | Incorporated by reference to the Registrant’ Report on Form 10-K dated February 25, 2020 (File |
No. 001-14010).
10-K
10-K.
| Item | 16: Form 10-K Summary |
The optional summary in Item 16 has not been included in this Form
10-K.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Waters Corporation |
| /s/ Sherry L. Buck |
| Sherry L. Buck |
| Senior Vice President and |
| Chief Financial Officer |
Date: February 25, 2020
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 25, 2020.
| /s/ Christopher J. O’Connell | | Chairman of the Board of Directors and Chief |
| Christopher J. O’Connell | | Executive Officer (principal executive officer) |
| /s/ Sherry L. Buck | | Senior Vice President and Chief Financial Officer |
| Sherry L. Buck | | (principal financial officer) (principal accounting officer) |
| /s/ Linda Baddour | | Director |
| Linda Baddour | | |
| /s/ Dr. Michael J. Berendt | | Director |
| Dr. Michael J. Berendt | | |
| /s/ Edward Conard | | Director |
| Edward Conard | | |
| /s/ Dr. Laurie H. Glimcher | | Director |
| Dr. Laurie H. Glimcher | | |
| /s/ Gary Hendrickson | | Director |
| Gary Hendrickson | | |
| /s/ Christopher A. Kuebler | | Director |
| Christopher A. Kuebler | | |
| /s/ Flemming Ornskov | | Director |
| Flemming Ornskov | | |
| /s/ JoAnn A. Reed | | Director |
| JoAnn A. Reed | | |
| /s/ Thomas P. Salice | | Director |
| Thomas P. Salice | | |
An excerpt. Shown here: 40 of 64 rewritten, all 17 added and all 36 removed. The counts are complete. For every sentence, read Item 15. Exhibits, Financial Statement Schedules in the FY2020 filing and the FY2019 filing.
Item 16. Form 10-K Summary
0 rewritten, 34 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2020 item · filed February 24, 2021
The optional summary in Item 16 has not been included in this Form
10-K.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| WATERS CORPORATION |
| /s/ Michael F. Silveira |
| Michael F. Silveira |
| Interim Chief Financial Officer |
| (principal financial officer) |
| (principal accounting officer) |
Date: February 24, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 24, 2021.
| /s/ Dr. Flemming Ornskov, M.D., M.P.H. | | Chairman of the Board of Directors |
| Dr. Flemming Ornskov, M.D., M.P.H. | | |
| /s/ Dr. Udit Batra | | President and Chief Executive Officer |
| Dr. Udit Batra | | Director (principal executive officer) |
| /s/ Michael F. Silveira | | Interim Chief Financial Officer |
| Michael F. Silveira | | (principal financial officer) (principal accounting officer) |
| /s/ Linda Baddour | | Director |
| Linda Baddour | | |
| /s/ Dr. Michael J. Berendt | | Director |
| Dr. Michael J. Berendt | | |
| /s/ Edward Conard | | Director |
| Edward Conard | | |
| /s/ Dr. Pearl S. Huang | | Director |
| Dr. Pearl S. Huang | | |
| /s/ Gary Hendrickson | | Director |
| Gary Hendrickson | | |
| /s/ Christopher A. Kuebler | | Director |
| Christopher A. Kuebler | | |
| /s/ JoAnn A. Reed | | Director |
| JoAnn A. Reed | | |
| /s/ Thomas P. Salice | | Director |
| Thomas P. Salice | | |